Cargando…

Intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter

INTRODUCTION: Data on patients with long-term exposure to ART is scarce because controlled studies usually do not follow up patients for more than five to seven years. We were interested whether baseline parameters such as CD4 T-cell nadir or pre-treatment viraemia do have an impact on ART success a...

Descripción completa

Detalles Bibliográficos
Autores principales: Erdbeer, Gesa, Sabranski, Michael, Sonntag, Ina, Stoehr, Albrecht, Horst, Heinz-A, Plettenberg, Andreas, Schewe, Knud, Unger, Stefan, Stellbrink, Hans-J, Fenske, Stefan, Hoffmann, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225443/
https://www.ncbi.nlm.nih.gov/pubmed/25397439
http://dx.doi.org/10.7448/IAS.17.4.19689
_version_ 1782343508631224320
author Erdbeer, Gesa
Sabranski, Michael
Sonntag, Ina
Stoehr, Albrecht
Horst, Heinz-A
Plettenberg, Andreas
Schewe, Knud
Unger, Stefan
Stellbrink, Hans-J
Fenske, Stefan
Hoffmann, Christian
author_facet Erdbeer, Gesa
Sabranski, Michael
Sonntag, Ina
Stoehr, Albrecht
Horst, Heinz-A
Plettenberg, Andreas
Schewe, Knud
Unger, Stefan
Stellbrink, Hans-J
Fenske, Stefan
Hoffmann, Christian
author_sort Erdbeer, Gesa
collection PubMed
description INTRODUCTION: Data on patients with long-term exposure to ART is scarce because controlled studies usually do not follow up patients for more than five to seven years. We were interested whether baseline parameters such as CD4 T-cell nadir or pre-treatment viraemia do have an impact on ART success after more than a decade of treatment. METHODS: ELBE is a cross-sectional study on adult HIV+ patients presenting consecutively with viral suppression (<50 HIV RNA copies/mL) and with ART exposure of at least five years. In this sub-analysis, all patients with more than 10 years of ART exposure were evaluated for immune reconstitution and for intermittent transient viraemia (50–1000 copies/mL, defined as “blips”) during the last five years. RESULTS: From a total of 894 patients included in the three participating ELBE centres, 524 patients had an ART exposure of at least 10 years and had been treated continuously during the last 5 years. Of these, 33.4% had at least one “blip” while 63.5% did not show any transient viraemia of more than 50 copies/mL. Patients with at least one blip had a higher pre-treatment viraemia compared to patients without blips (5.30 versus 5.06 log copies/mL, p=0.0003). In patients with a pre-treatment viraemia of more than 100,000, 50,000–100,000 and less than 50,000 copies/mL, the proportions of patients with blips during the last five years were 39.5%, 30.5% and 21.8% (p=0.007), respectively. The history of an AIDS-defining illness or the CD4 T-cell nadir was not associated with a higher frequency of blips. However, CD4 T-cell nadir was a strong predictor for current CD4 T-cell counts. In patient groups with a CD4 T-cell nadir of 0–99, 100–199, 200–349, 350+ cells/µL, the median current CD4 T cells were 571, 667, 710 and 890 cells/µL, respectively. These differences remained significant when the analysis was restricted to patients with more than 15 years of ART exposure (n=268). CONCLUSIONS: In this large group of positively selected HIV+ patients with long-term exposure to ART of at least 10–15 years, high pre-treatment viraemia was still associated with a higher frequency of intermittent transient viraemia (“blip”). A low CD4 T-cell nadir remained associated with a lower CD4 cell recovery. The clinical implications of these findings remain to be evaluated.
format Online
Article
Text
id pubmed-4225443
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-42254432014-11-12 Intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter Erdbeer, Gesa Sabranski, Michael Sonntag, Ina Stoehr, Albrecht Horst, Heinz-A Plettenberg, Andreas Schewe, Knud Unger, Stefan Stellbrink, Hans-J Fenske, Stefan Hoffmann, Christian J Int AIDS Soc Poster Sessions – Abstract P157 INTRODUCTION: Data on patients with long-term exposure to ART is scarce because controlled studies usually do not follow up patients for more than five to seven years. We were interested whether baseline parameters such as CD4 T-cell nadir or pre-treatment viraemia do have an impact on ART success after more than a decade of treatment. METHODS: ELBE is a cross-sectional study on adult HIV+ patients presenting consecutively with viral suppression (<50 HIV RNA copies/mL) and with ART exposure of at least five years. In this sub-analysis, all patients with more than 10 years of ART exposure were evaluated for immune reconstitution and for intermittent transient viraemia (50–1000 copies/mL, defined as “blips”) during the last five years. RESULTS: From a total of 894 patients included in the three participating ELBE centres, 524 patients had an ART exposure of at least 10 years and had been treated continuously during the last 5 years. Of these, 33.4% had at least one “blip” while 63.5% did not show any transient viraemia of more than 50 copies/mL. Patients with at least one blip had a higher pre-treatment viraemia compared to patients without blips (5.30 versus 5.06 log copies/mL, p=0.0003). In patients with a pre-treatment viraemia of more than 100,000, 50,000–100,000 and less than 50,000 copies/mL, the proportions of patients with blips during the last five years were 39.5%, 30.5% and 21.8% (p=0.007), respectively. The history of an AIDS-defining illness or the CD4 T-cell nadir was not associated with a higher frequency of blips. However, CD4 T-cell nadir was a strong predictor for current CD4 T-cell counts. In patient groups with a CD4 T-cell nadir of 0–99, 100–199, 200–349, 350+ cells/µL, the median current CD4 T cells were 571, 667, 710 and 890 cells/µL, respectively. These differences remained significant when the analysis was restricted to patients with more than 15 years of ART exposure (n=268). CONCLUSIONS: In this large group of positively selected HIV+ patients with long-term exposure to ART of at least 10–15 years, high pre-treatment viraemia was still associated with a higher frequency of intermittent transient viraemia (“blip”). A low CD4 T-cell nadir remained associated with a lower CD4 cell recovery. The clinical implications of these findings remain to be evaluated. International AIDS Society 2014-11-02 /pmc/articles/PMC4225443/ /pubmed/25397439 http://dx.doi.org/10.7448/IAS.17.4.19689 Text en © 2014 Erdbeer G et al; licensee International AIDS Society http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Sessions – Abstract P157
Erdbeer, Gesa
Sabranski, Michael
Sonntag, Ina
Stoehr, Albrecht
Horst, Heinz-A
Plettenberg, Andreas
Schewe, Knud
Unger, Stefan
Stellbrink, Hans-J
Fenske, Stefan
Hoffmann, Christian
Intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter
title Intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter
title_full Intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter
title_fullStr Intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter
title_full_unstemmed Intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter
title_short Intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter
title_sort intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter
topic Poster Sessions – Abstract P157
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225443/
https://www.ncbi.nlm.nih.gov/pubmed/25397439
http://dx.doi.org/10.7448/IAS.17.4.19689
work_keys_str_mv AT erdbeergesa intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter
AT sabranskimichael intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter
AT sonntagina intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter
AT stoehralbrecht intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter
AT horstheinza intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter
AT plettenbergandreas intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter
AT scheweknud intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter
AT ungerstefan intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter
AT stellbrinkhansj intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter
AT fenskestefan intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter
AT hoffmannchristian intermittentviraemiaandimmunereconstitutioninpatientswithmorethan1015yearsofantiretroviraltherapybaselinevaluesstillmatter